Janssen’s Erleada maintains quality of life for prostate cancer patients
27th May 2021
Janssen’s Erleada in addition to androgen deprivation therapy (ADT) maintained prostate cancer patients’ health-related quality of life (HRQoL), according to new patient-reported outcomes (PRO) data.
The PRO data from the prespecified final analysis of the Phase III TITAN study in patients with metastatic hormone-sensitive prostate cancer (mHSPC) also showed that the addition of Erleada (apalutamide) to ADT did not worse side effect burden.
In both treatment groups – patients who received Erleada plus ADT and patients who received placebo plus ADT – HRQoL was maintained throughout the study.